SREBF1 and metabolic dysfunction-associated steatotic liver disease: In cell lines and mouse models of NAFLD, abundant transcript 1 (NEAT1) binds miR-140 to exacerbate the progression through inactivating the AMPK–SREBP-1 pathway, presenting a new therapeutic strategy [43].